Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
MBRX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 15, 2026
Report Source: 2026 1st Quarter Report
Moleculin Biotech Inc. Stock Analysis MBRX
United States Health Care Nano Cap Report: Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Houston, Texas and currently employs 17 full-time employees. The company went IPO on 2016-06-02. The firm is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). The company has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
Read More Moleculin Biotech Inc (MBRX) Chart
Key Statistics of Moleculin Biotech Inc (MBRX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$2.61Volume
11.24MP/E Ratio (TTM)
-52 Week Range
Market Cap
12.75MAvg. Volume
815.79KDividend Yield
-Financial Metrics & Statements of Moleculin Biotech Inc (MBRX)
FAQ's for Moleculin Biotech Inc (MBRX)
- According to Musaffa’s Shariah screening methodology, Moleculin Biotech Inc (MBRX) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Moleculin Biotech Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Moleculin Biotech Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Moleculin Biotech Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Moleculin Biotech Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Moleculin Biotech Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.